NCT02109406View on ClinicalTrials.gov

Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

AZD2115 Dose 1

AZD 2115, Dose 1 administered as two inhalations BID

DRUG

AZD 2115, Dose 2

AZD 2115, Dose 2 administered as two inhalations BID

DRUG

Placebo MDI

Placebo MDI administered as two inhalations BID

Trial Locations (3)

Unknown

Pearl Therapeutics Study Site, Clearwater

Pearl Therapeutics Study Site, Charleston

Pearl Therapeutics Study Site, Spartanburg

Sponsors
All Listed Sponsors
lead

Pearl Therapeutics, Inc.

INDUSTRY